|
Nov 28
|
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
|
|
Sep 5
|
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Jun 22
|
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
|
|
Apr 26
|
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
|
|
Apr 25
|
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
|